MCID: PLM031
MIFTS: 55

Poliomyelitis

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Poliomyelitis

MalaCards integrated aliases for Poliomyelitis:

Name: Poliomyelitis 12 50 56 42 14 69
Infantile Paralysis 50 69
Polio 50 52

Characteristics:

Orphanet epidemiological data:

56
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4953
ICD10 33 A80 A80.9
ICD9CM 35 045 045.9
MeSH 42 D011051
NCIt 47 C35550
Orphanet 56 ORPHA2912
MESH via Orphanet 43 D011051
UMLS via Orphanet 70 C0032371
ICD10 via Orphanet 34 A80.0 A80.1 A80.2 more
UMLS 69 C0032371

Summaries for Poliomyelitis

NIH Rare Diseases : 50 poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. it is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. there are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic. symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. treatment is aimed at controlling symptoms while the infection runs its course. since the development of the polio vaccine, the incidence of the disease has been greatly reduced. the prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected. last updated: 12/24/2015

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to hepatitis b and louping ill. An important gene associated with Poliomyelitis is PVR (Poliovirus Receptor), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Phenol and Zinc have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and b cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results_in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted_by ingestion of food or water contaminated with feces, or transmitted_by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 72 Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 285)
id Related Disease Score Top Affiliating Genes
1 hepatitis b 30.6 IFNG IL10 TNF
2 louping ill 30.0 ICAM1 IFNG TNF
3 hemophagocytic lymphohistiocytosis 29.9 IFNG IL10 TNF
4 parametritis 29.8 IFNG TNF
5 nonparalytic poliomyelitis 12.3
6 paralytic poliomyelitis 12.2
7 poliomyelitis in patients with immunodeficiencies deemed at risk 11.8
8 bulbar polio 11.5
9 postpoliomyelitis syndrome 11.0
10 spastic diplegia 10.8
11 pure autonomic failure 10.8 IL10 TNF
12 motor neuron disease 10.7
13 spinal polio 10.7
14 bulbospinal polio 10.7
15 west nile fever 10.7
16 multiple familial trichoepithelioma 10.7 IL10 TNF
17 sternal cleft 10.7 IFNG TNF
18 type 1 papillary adenoma of the kidney 10.7 IL10 TNF
19 autoimmune polyglandular syndrome type 3 10.7 IFNG TNF
20 endosalpingiosis 10.7 IL10 TNF
21 mosaic trisomy 1 10.7 IFNG TNF
22 myoclonic astatic epilepsy 10.7 IFNG IL4
23 primary systemic mycosis 10.7 IFNG TNF
24 idiopathic dilatation of the pulmonary artery 10.7 IL10 TNF
25 ethmoid sinus adenocarcinoma 10.6 IL10 TNF
26 tarsal tunnel syndrome 10.6 IL10 TNF
27 graft-versus-host disease, protection against 10.6 IFNG IL10
28 dumping syndrome 10.6 IFNG IL10
29 diabetic angiopathy 10.6 IL10 IL4
30 urethral intrinsic sphincter deficiency 10.6 IL4 TNF
31 deafness, autosomal recessive 22 10.6 IL10 IL4
32 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.6 IFNG IL10
33 goat milk allergy 10.5 IFNG IL4
34 x-linked intellectual disability, van esch type 10.5 IFNG IL4
35 gerstmann syndrome 10.5 IFNG IL10
36 cherry allergy 10.5 IL10 IL4
37 amyotrophic lateral sclerosis type 10 10.5 IFNG TNF
38 cow milk allergy 10.5 IL10 IL4
39 barmah forest virus disease 10.5 DPT PVR
40 strawberry gallbladder 10.5 IFNG IL10
41 chronic apical periodontitis 10.5 IL10 TNF
42 pasteurellosis 10.5 IFNG TNF
43 hypercalcinuria macular coloboma 10.5 IFNG IL4
44 plantar wart 10.5 IFNG IL10 TNF
45 acute ackee fruit intoxication 10.5 IL10 IL4 TNF
46 cyclosporiasis 10.5 IFNG IL10 TNF
47 hepadnavirus infection 10.5 IFNG IL10 TNF
48 senile reticular retinal degeneration 10.5 IFNG IL10 TNF
49 psychologic dyspareunia 10.5 IFNG IL10 TNF
50 bartonellosis 10.4 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

MGI Mouse Phenotypes related to Poliomyelitis:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 DLG1 FCGR2A FCGR3B ICAM1 IFNG IL10
2 immune system MP:0005387 10.09 DLG1 FCGR2A FCGR3B ICAM1 IFNG IL10
3 digestive/alimentary MP:0005381 10.04 TNF DLG1 ICAM1 IFNG IL10 IL4
4 endocrine/exocrine gland MP:0005379 10.02 LEP TNF DLG1 ICAM1 IFNG IL10
5 integument MP:0010771 9.95 IFNG IL10 IL4 LEP TNF DPT
6 muscle MP:0005369 9.85 DLG1 ICAM1 IFNG IL10 LEP TNF
7 no phenotypic analysis MP:0003012 9.73 DLG1 FCGR3B IFNG IL10 IL4 TNF
8 neoplasm MP:0002006 9.72 ICAM1 IFNG IL10 LEP TNF
9 respiratory system MP:0005388 9.63 DLG1 IFNG IL10 IL4 LEP TNF
10 skeleton MP:0005390 9.56 DLG1 FCGR2A FCGR3B IFNG IL10 IL4
11 vision/eye MP:0005391 9.23 DLG1 DPT ICAM1 IFNG IL10 IL4

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenol Approved, Experimental Phase 4 108-95-2 996
2
Zinc Approved Phase 4 7440-66-6 32051 23994
3 Zinc sulfate Approved Phase 4 7733-02-0
4
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
5
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
6
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
7
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Menthol Approved Phase 4 2216-51-5 16666
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 11103-57-4, 68-26-8 445354
11
BCG vaccine Investigational Phase 4,Phase 2
12 Antibodies Phase 4,Phase 2,Phase 3
13 Antibodies, Blocking Phase 4
14 Immunoglobulins Phase 4,Phase 2,Phase 3
15 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Micronutrients Phase 4,Phase 2,Phase 3
17 Trace Elements Phase 4,Phase 2,Phase 3
18 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Antioxidants Phase 4,Phase 2,Phase 3
20 Protective Agents Phase 4,Phase 3,Phase 2
21 Retinol palmitate Phase 4,Phase 2,Phase 3
22 Vitamins Phase 4,Phase 2,Phase 3
23 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
25 Polymyxin B Phase 4
26 Polymyxins Phase 4
27 Anticoagulants Phase 4,Phase 3,Phase 2
28 Fibrinolytic Agents Phase 4,Phase 3
29 PENTA Phase 4,Phase 3
30 Antidotes Phase 4,Phase 3,Phase 2
31 Calcium, Dietary Phase 4,Phase 3,Phase 2
32 Chelating Agents Phase 4,Phase 3,Phase 2
33 Iron Chelating Agents Phase 4,Phase 3,Phase 2
34 Pentetic Acid Phase 4,Phase 3,Phase 2
35 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
36 Analgesics Phase 4,Phase 3
37 Analgesics, Non-Narcotic Phase 4,Phase 3
38 Anti-Inflammatory Agents Phase 4,Phase 2
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Antipyretics Phase 4,Phase 3
41 Antirheumatic Agents Phase 4
42 Cyclooxygenase Inhibitors Phase 4
43 Peripheral Nervous System Agents Phase 4,Phase 3
44 Adjuvants, Immunologic Phase 4,Phase 1,Phase 2
45 retinol Nutraceutical Phase 4,Phase 2,Phase 3
46 Acidophilus Nutraceutical Phase 4
47 Zinc Supplement Nutraceutical Phase 4
48
Pyrimethamine Approved, Vet_approved Phase 2, Phase 3,Phase 1 58-14-0 4993
49
Sulfadoxine Approved Phase 2, Phase 3,Phase 1 2447-57-6 17134
50
Aluminum hydroxide Approved Phase 3,Phase 1,Phase 2 21645-51-2

Interventional clinical trials:

(show top 50) (show all 319)

id Name Status NCT ID Phase Drugs
1 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
2 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
3 A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China Completed NCT01278433 Phase 4
4 Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine Completed NCT01475539 Phase 4
5 A Study of the Safety of IMOVAX Polio™ in China Completed NCT01244464 Phase 4
6 Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
7 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
8 A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age Completed NCT02580201 Phase 4
9 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
10 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
11 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
12 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines Completed NCT01616693 Phase 4
13 A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Completed NCT02582255 Phase 4
14 A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children Completed NCT02521974 Phase 4
15 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
16 Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Completed NCT01831050 Phase 4
17 Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules Completed NCT02412514 Phase 4
18 Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine Completed NCT02643368 Phase 4
19 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia Completed NCT01094171 Phase 4
20 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
21 IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi. Completed NCT01695798 Phase 4
22 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4 IPV IM Needle;IPV ID Needle;IPV IM Device;IPV ID Device
23 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
24 Inactivated Influenza Vaccine Effectiveness in Tropical Africa Completed NCT00893906 Phase 4
25 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
26 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
27 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
28 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
29 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
30 Poliovirus Vaccine Trial in Bangladesh Completed NCT01633216 Phase 4
31 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
32 Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV Completed NCT03310073 Phase 4
33 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
34 Different Doses of Vitamin A and Childhood Morbidity and Mortality Completed NCT00168584 Phase 4 Vitamin A
35 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
36 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
37 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
38 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
39 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
40 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
41 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
42 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
43 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4
44 Influenza Immunization of Children in India Completed NCT01680679 Phase 4
45 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
46 Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Completed NCT00772369 Phase 4
47 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4 Paracetamol;Ibuprofen;Paracetamol;Ibuprofen
48 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Recruiting NCT03147560 Phase 4
49 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Recruiting NCT02422264 Phase 4 Prevnar13
50 Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan Recruiting NCT03286803 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

MalaCards organs/tissues related to Poliomyelitis:

39
Brain, Spinal Cord, B Cells, Liver, Bone, Testes, Lung

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 973)
id Title Authors Year
1
Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis. ( 28604777 )
2017
2
A systematic review of the worldwide prevalence of survivors of poliomyelitis reported in 31 studies. ( 28694346 )
2017
3
Progress Toward Poliomyelitis Eradication - Afghanistan, January 2016-June 2017. ( 28817551 )
2017
4
Understanding the Dynamics of Poliomyelitis Spread in Pakistan. ( 28845415 )
2017
5
Epidemiological Surveillance of Poliomyelitis During the Military and Political Conflict in the Central African Republic, 2013 and 2014. ( 28480271 )
2017
6
Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis. ( 28356537 )
2017
7
Virologic monitoring of poliovirus type 2 after OPV2 withdrawal in April 2016: an important advance in eradicating poliomyelitis and eliminating live oral poliovirus vaccines worldwide, 2016a892017. ( 28547947 )
2017
8
Combined tibial lengthening and ankle arthrodesis for patients with certain type of sequelae of poliomyelitis. ( 28117634 )
2017
9
Feasibility of using global system for mobile communication (GSM)-based tracking for vaccinators to improve oral poliomyelitis vaccine campaign coverage in rural Pakistan. ( 28802756 )
2017
10
175 Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2017. ( 28387112 )
2017
11
Poliomyelitis eradication a89 the review of notifications from the years 2010-2016 sent to National IHR Focal Point ( 28654739 )
2017
12
An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. ( 28549485 )
2017
13
Post-marketing surveillance study to assess the safety and tolerability of an Inactivated Poliomyelitis Vaccine in Indian children. ( 28846490 )
2017
14
Progress towards poliomyelitis eradication: Afghanistan, January 2016a89June 2017. ( 28819963 )
2017
15
Knowledge assessment regarding poliomyelitis among the caregivers of children who received oral polio vaccine reveals lack of awareness of the vaccine vial monitor (VVM): Implications extending beyond polio eradication. ( 28121284 )
2017
16
Assessment of energy expenditure in individuals with post-poliomyelitis syndrome. ( 28355321 )
2017
17
Vaccine Associated Paralytic Poliomyelitis Unmasking Common Variable Immunodeficiency. ( 28361789 )
2017
18
Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization. ( 28057194 )
2017
19
Morbidity and mortality following poliomyelitis - a lifelong follow-up. ( 27869331 )
2017
20
Negative or positive? The iron lung and poliomyelitis-Zurich, 1951. ( 28675796 )
2017
21
Acute segmental poliomyelitis-like flaccid paralysis in an adult in the UK, associated with enterovirus D68. ( 28626021 )
2017
22
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial. ( 28362135 )
2017
23
A case-control study on the association of pulse oral poliomyelitis vaccination and Gianotti-Crosti syndrome. ( 27943306 )
2017
24
Effective case/infection ratio of poliomyelitis in vaccinated populations. ( 26830060 )
2016
25
Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2015. ( 27086368 )
2016
26
Winning the battle against the scourge of poliomyelitis in the African Region. ( 27576072 )
2016
27
Progress Toward Poliomyelitis Eradication - Pakistan, January 2015-September 2016. ( 27880752 )
2016
28
Comprehensive review of challenges associated with management of lower limb fractures in poliomyelitis patients. ( 27857503 )
2016
29
Franklin Delano Roosevelt: The Diagnosis of Poliomyelitis Revisited. ( 27178375 )
2016
30
556 Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2016. ( 27922012 )
2016
31
Outcomes of total hip replacement in limbs affected by poliomyelitis. ( 27886358 )
2016
32
A cluster of paralytic poliomyelitis cases due to transmission of slightly diverged Sabin-2 vaccine virus. ( 27099315 )
2016
33
Poliomyelitis in Ancient Egypt? ( 27665570 )
2016
34
Shoulder arthroplasty for sequelae of poliomyelitis. ( 26700552 )
2016
35
International Health Regulations in practice: Focus on yellow fever and poliomyelitis. ( 27541082 )
2016
36
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. ( 26803328 )
2016
37
Fixator-assisted tibial lengthening over a plate in a patient with sequelae of poliomyelitis. ( 27858886 )
2016
38
Quadracel: Vaccination Against Diphtheria, Tetanus, Pertussis, and Poliomyelitis in Children. ( 27069343 )
2016
39
Poliomyelitis: residual hurdles to global eradication. Commentary. ( 27999213 )
2016
40
Faster Detection of Poliomyelitis Outbreaks to Support Polio Eradication. ( 26890053 )
2016
41
Placental antibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies. ( 27934956 )
2016
42
Outcome after cementless total hip arthroplasty for arthritic hip in patients with residual poliomyelitis: a case series. ( 27229169 )
2016
43
A Transgenic Mouse Model of Poliomyelitis. ( 26983733 )
2016
44
A human quadrupedal gait following poliomyelitis: From the Dercum-Muybridge collaboration (1885). ( 26928358 )
2016
45
Progress towards poliomyelitis eradication: Afghanistan, January 2015a89August 2016. ( 27811982 )
2016
46
Intrathecal Analgesic Drug Delivery is Effective for Analgesia in a Patient with Post-Poliomyelitis Syndrome: A Case Report. ( 27980323 )
2016
47
Outcomes of Total Knee Arthroplasty in Patients With Poliomyelitis. ( 27259390 )
2016
48
Progress Toward Poliomyelitis Eradication - Afghanistan, January 2015a89August 2016. ( 27811838 )
2016
49
The effect of footwear adapted with a multi-curved rocker sole in conjunction with knee-ankle-foot orthoses on walking in poliomyelitis subjects: a pilot study. ( 27982715 )
2016
50
Experiences of attitudes in Sierra Leone from the perspective of people with poliomyelitis and amputations using orthotics and prosthetics. ( 27829289 )
2016

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 41)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 FCGR2A FCGR3A FCGR3B ICAM1 IFNG IL10
2
Show member pathways
12.75 ICAM1 IFNG IL10 IL4 TNF
3
Show member pathways
12.68 ICAM1 IFNG IL4 TNF
4
Show member pathways
12.52 IFNG IL10 IL4 TNF
5
Show member pathways
12.49 IFNG IL10 IL4 TNF
6 12.46 IFNG IL10 IL4 PVR TNF
7
Show member pathways
12.43 FCGR3A FCGR3B ICAM1 IFNG IL4 TNF
8
Show member pathways
12.35 DLG1 IFNG IL10 IL4 TNF
9
Show member pathways
12.14 IFNG IL10 IL4 LEP
10
Show member pathways
12.09 IFNG IL10 IL4 TNF
11
Show member pathways
12.07 IFNG IL4 TNF
12 12.05 FCGR2A FCGR3A FCGR3B IFNG IL10 TNF
13 12.03 FCGR2A FCGR3A FCGR3B
14 11.99 ICAM1 IFNG TNF
15 11.97 FCGR3A ICAM1 PVR
16 11.96 FCGR2A FCGR3A FCGR3B IFNG TNF
17 11.91 ICAM1 IL10 IL4 TNF
18 11.87 FCGR2A IFNG IL10 IL4 TNF
19
Show member pathways
11.86 IFNG IL10 TNF
20 11.8 IFNG IL10 TNF
21 11.77 ICAM1 IFNG TNF
22
Show member pathways
11.77 FCGR2A FCGR3A FCGR3B IFNG IL10 IL4
23 11.73 IFNG IL10 IL4 TNF
24 11.72 ICAM1 IFNG IL4
25 11.71 FCGR2A ICAM1 IFNG IL4 LEP TNF
26
Show member pathways
11.68 IFNG IL4 TNF
27 11.68 IFNG IL10 TNF
28
Show member pathways
11.59 ICAM1 IFNG TNF
29 11.5 ICAM1 IL10 IL4 TNF
30 11.49 ICAM1 IFNG IL10 TNF
31 11.45 IFNG IL10 IL4
32 11.4 FCGR2A FCGR3A FCGR3B ICAM1 IL10
33
Show member pathways
11.37 IFNG IL10 TNF
34 11.28 ICAM1 IFNG IL10 TNF
35 11.27 IFNG IL4 TNF
36 11.15 IFNG IL10 IL4
37 11.15 IFNG IL10 IL4 TNF
38 11.08 ICAM1 IFNG
39 11.02 LEP TNF
40 11.01 FCGR2A FCGR3A FCGR3B ICAM1 IL10 IL4
41 10.86 ICAM1 TNF

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 FCGR3B IFNG IL10 IL4 LEP PVR
2 extracellular space GO:0005615 9.56 DPT ICAM1 IFNG IL10 IL4 LEP
3 external side of plasma membrane GO:0009897 9.02 FCGR3A ICAM1 IFNG IL4 TNF

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 39)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 ICAM1 IFNG IL10 IL4
2 positive regulation of protein phosphorylation GO:0001934 9.85 IFNG IL4 TNF
3 response to ethanol GO:0045471 9.83 ICAM1 IL4 LEP
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.82 IL10 IL4 TNF
5 single organismal cell-cell adhesion GO:0016337 9.82 DLG1 ICAM1 PVR
6 immune response GO:0006955 9.8 FCGR3A FCGR3B IFNG IL10 IL4 TNF
7 response to insulin GO:0032868 9.78 ICAM1 IL10 LEP
8 regulation of insulin secretion GO:0050796 9.77 IFNG LEP TNF
9 positive regulation of T cell proliferation GO:0042102 9.76 IFNG IL4 LEP
10 cellular response to lipopolysaccharide GO:0071222 9.73 ICAM1 IFNG IL10 TNF
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 ICAM1 IFNG TNF
12 positive regulation of protein complex assembly GO:0031334 9.68 IFNG TNF
13 cortical actin cytoskeleton organization GO:0030866 9.67 DLG1 TNF
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 IL10 TNF
15 positive regulation of osteoclast differentiation GO:0045672 9.67 IFNG TNF
16 negative regulation of nitric oxide biosynthetic process GO:0045019 9.66 IL10 IL4
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.66 IFNG TNF
18 leukocyte tethering or rolling GO:0050901 9.65 LEP TNF
19 negative regulation of mitotic cell cycle GO:0045930 9.65 DLG1 IL10 TNF
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 IL10 TNF
21 negative regulation of glucose import GO:0046325 9.63 LEP TNF
22 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 IFNG IL4
23 negative regulation of lipid storage GO:0010888 9.62 LEP TNF
24 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.59 IFNG IL4
26 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.58 ICAM1 TNF
27 negative regulation of endothelial cell apoptotic process GO:2000352 9.58 ICAM1 IL10 IL4
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 IL10 TNF
29 type 2 immune response GO:0042092 9.56 IL10 IL4
30 regulation of isotype switching GO:0045191 9.55 IL10 IL4
31 regulation of immune response GO:0050776 9.55 FCGR3A ICAM1 IFNG IL4 PVR
32 positive regulation of mononuclear cell migration GO:0071677 9.54 IL4 TNF
33 defense response to protozoan GO:0042832 9.54 IFNG IL10 IL4
34 receptor biosynthetic process GO:0032800 9.51 IL10 TNF
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
36 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 IFNG TNF
37 negative regulation of growth of symbiont in host GO:0044130 9.43 IFNG IL10 TNF
38 positive regulation of chemokine biosynthetic process GO:0045080 9.13 IFNG IL4 TNF
39 positive regulation of MHC class II biosynthetic process GO:0045348 8.8 IFNG IL10 IL4

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 IL10 IL4 LEP
2 cytokine activity GO:0005125 9.26 IFNG IL10 IL4 TNF
3 IgG binding GO:0019864 8.8 FCGR2A FCGR3A FCGR3B

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....